Janssen, Harry LHarry LJanssenLim, Young-SukYoung-SukLimKim, Hyung JoonHyung JoonKimSowah, LeonardLeonardSowahTseng, Cheng-HaoCheng-HaoTsengCoffin, Carla SCarla SCoffinElkhashab, MagdyMagdyElkhashabAhn, Sang HoonSang HoonAhnNguyen, Anh-HoaAnh-HoaNguyenChen, DianaDianaChenWallin, Jeffrey JJeffrey JWallinFletcher, Simon PSimon PFletcherMcDonald, CirceCirceMcDonaldYang, Jenny CJenny CYangGaggar, AnujAnujGaggarBrainard, Diana MDiana MBrainardFung, ScottScottFungKim, Yoon JunYoon JunKimJIA-HORNG KAOChuang, Wan-LongWan-LongChuangBrooks, Anna EAnna EBrooksDunbar, P RodP RodDunbar2024-03-012024-03-012024-0225895559https://scholars.lib.ntu.edu.tw/handle/123456789/640066Novel finite therapies for chronic hepatitis B (CHB) are needed, since lifelong treatment is usually required with current available oral antivirals. This phase II study (NCT03615066) evaluated the safety, pharmacodynamics, and antiviral activity of selgantolimod (a Toll-like receptor 8 agonist [TLR8]) with tenofovir alafenamide (TAF).enHBV cure; Hepatitis B virus; immunotherapy; oral antiviral; small molecule; toll-like receptor; viremicjournal article10.1016/j.jhepr.2023.100975382744922-s2.0-85181820749https://api.elsevier.com/content/abstract/scopus_id/85181820749